Varicella Zoster Infection Treatment Market
Varicella Zoster Infection Treatment Market: Purchases from Drug Stores to Rise as Demand for Topicals Take a Surge: Global Industry Analysis (2012 - 2016) & Opportunity Assessment (2017 - 2027)
- 2018-03-21
- REP-GB-6466
- 276 pages
-
An Incisive, In-depth Analysis on the Varicella Zoster Infection Treatment Market
This study offers a comprehensive, 360 degree analysis on the Varicella Zoster Infection Treatment market, bringing to fore insights that can help stakeholders identify the opportunities as well as challenges. It tracks the global Varicella Zoster Infection Treatment market across key regions, and offers in-depth commentary and accurate quantitative insights. The study also includes incisive competitive landscape analysis, and provides key recommendations to market players on winning imperatives and successful strategies.
COVID -19 : Impact Analysis
Request the coronavirus impact analysis across industries and markets
Request Covid -19 ImpactVaricella zoster spreads easily from people with chickenpox to others who never had the disease or been vaccinated. It can be transmitted by respiratory droplets, from skin lesions, by direct contact or possibly by aerosolisation of the virus from skin lesions. Chickenpox can spread from people with shingles to others who never had chickenpox or received the chickenpox vaccine. According to a study of the Centers of Disease Control and Prevention, transmission of varicella is high among household members. About 90% of varicella cases are susceptible to close contact with people suffering from varicella. In schools and day care centres the transmission rate among susceptible children tend to be lower than 30%–50%. Varicella occurs worldwide with ongoing endemic transmission in areas where the population is sufficiently large to support such transmission.
Purchase of drugs through hospital pharmacies to increase in the coming years
Pregnant women, kids, and the geriatric population have the highest risks of developing a varicella zoster infection. As a result, if any person or kid is infected, they are either admitted or prescribed specific medicines or drugs for the treatment of the varicella zoster infection. Some of the medicines are only sold by hospital pharmacies as these medicines can only be bought if prescribed by a doctor or medical practitioner. Stringent regulations are also another reason for an increasing number of purchases from hospital pharmacies. The FDA regulatory approval process for drugs is strict. Therefore, these challenges in the regulatory environment are prompting investors in the industry to shift their investments overseas, which may act as a restraint for the growth of the varicella zoster infection treatment market. Most of the companies are facing difficulties in bringing herpes zoster drugs and vaccines to the market without the necessary FDA approvals. As a result, the approved drugs can only be bought if prescribed by a qualified healthcare professional and from specific hospital pharmacies.
Retail pharmacies to get a boost with increasing healthcare expenditure and an advanced healthcare model
According to the IMF, global healthcare expenditure is expected to increase by over 6% yearly, based on the current GDP forecast. The rising geriatric population in developed countries and growing affluence in emerging markets are likely to boost healthcare expenditure. In the U.S., prescription drugs comprise 10% of the national health expenditure and this is expected to increase in the coming years. Besides, high spending on prescription drugs is attributed to the increased spending on new medicines, increased spending on generics, price rise of existing branded drugs, and fewer expensive blockbuster drugs going off-patent.
The governments and regulatory bodies of several countries are adopting various cost containment measures to reduce the healthcare burden, especially in developed economies. This change from a volume- to a value-based system is driven by various measures taken by the governments, healthcare providers, payers and pharmaceutical companies, which include outcome-based pricing, profit and risk sharing, price control and competitive tendering. The value-based healthcare model is expected to help achieve supreme value for money spent on healthcare and thus improve the outcomes through integrated care pathways. Nevertheless, at the same time it would levy pricing pressure on biopharmaceutical and medtech companies, which may impact R&D investment for innovative medical treatment technologies. As a result of all these factors, the demand for bulk medicines is increasing and as retail pharmacies are the best place to obtain medicines in bulk, these pharmacies are getting a good push in the global market.
Global Healthcare Sector Outlook
Despite the economic and political uncertainty in the recent past, the global healthcare industry has been receiving positive nudges from reformative and technological disruptions in medical devices, pharmaceuticals and biotech, in-vitro diagnostics, and medical imaging. Key markets across the world are facing a massive rise in demand for critical care services that are pushing global healthcare spending levels to unimaginable limits.
A rapidly multiplying geriatric population; increasing prevalence of chronic ailments such as cancer and cardiac disease; growing awareness among patients; and heavy investments in clinical innovation are just some of the factors that are impacting the performance of the global healthcare industry. Proactive measures such as healthcare cost containment, primary care delivery, innovation in medical procedures (3-D printing, blockchain, and robotic surgery to name a few), safe and effective drug delivery, and well-defined healthcare regulatory compliance models are targeted at placing the sector on a high growth trajectory across key regional markets.
Parent Indicators Healthcare
-
Current expenditure on health, % of gross domestic product
-
Current expenditure on health, per capita, US$ purchasing power parities (current prices, current PPPs)
-
Annual growth rate of current expenditure on health, per capita, in real terms
-
Out-of-pocket expenditure, % of current expenditure on health
-
Out-of-pocket expenditure, per capita, US$ purchasing power parity (current prices, current PPPs)
-
Physicians, Density per 1000 population (head counts)
-
Nurses, Density per 1000 population (head counts)
-
Total hospital beds, per 1000 population
-
Curative (acute) care beds, per 1000 population
-
Medical technology, Magnetic Resonance Imaging units, total, per million population
-
Medical technology, Computed Tomography scanners, total, per million population
Research Methodology
FMI utilizes a triangulation methodology that is primarily based on experimental techniques such as patient-level data, to obtain precise market estimations and insights on Molecule and Drug Classes, API Formulations and preferred modes of administration. Bottom-up approach is always used to obtain insightful data for the specific country/regions. The country specific data is again analysed to derive data at a global level. This methodology ensures high quality and accuracy of information.
Secondary research is used at the initial phase to identify the age specific disease epidemiology, diagnosis rate and treatment pattern, as per disease indications. Each piece of information is eventually analysed during the entire research project which builds a strong base for the primary research information.
Primary research participants include demand-side users such as key opinion leaders, physicians, surgeons, nursing managers, clinical specialists who provide valuable insights on trends and clinical application of the drugs, key treatment patterns, adoption rate, and compliance rate.
Quantitative and qualitative assessment of basic factors driving demand, economic factors/cycles and growth rates and strategies utilized by key players in the market is analysed in detail while forecasting, in order to project Year-on-Year growth rates. These Y-o-Y growth projections are checked and aligned as per industry/product lifecycle and further utilized to develop market numbers at a holistic level.
On the other hand, we also analyse various companies annual reports, investor presentations, SEC filings, 10k reports and press release operating in this market segment to fetch substantial information about the market size, trends, opportunity, drivers, restraints and to analyse key players and their market shares. Key companies are segmented at Tier level based on their revenues, product portfolio and presence.
Please note that these are the partial steps that are being followed while developing the market size. Besides this, forecasting will be done based on our internal proprietary model which also uses different macro-economic factors such as per capita healthcare expenditure, disposable income, industry based demand driving factors impacting the market and its forecast trends apart from disease related factors.
Standard Report Structure
-
Executive Summary
-
Market Definition
-
Macro-economic analysis
-
Parent Market Analysis
-
Market Overview
-
Forecast Factors
-
Segmental Analysis and Forecast
-
Regional Analysis
-
Competition Analysis
Market Taxonomy
|
Drug Type |
Route of Administration |
Distribution Channel |
Region |
|---|---|---|---|
|
|
|
|
Report Methodology
The analyst has used the epidemiology model and has calculated the incidence rate among old age people, pregnant women, and children to arrive at certain assumptions about this market.
Get in touch
Harish Tiwari
Global Head - Business Development
Our Clients
CASE STUDIES
See how our work makes an impact.
At FMI, we design strategies that are adaptive, impactful, and implementable.